Avanir Pharmaceuticals Raises $230M In Public Offering

Aliso Viejo-based Avanir Pharmaceuticals has raised another $230M, via the public markets, the company said Monday. The company said the funding came via a public offering of 20,930,000 shares of its common stock, sold at $11.00 per share. The company was already publicly traded. The company said the new funding will go towards general corporate purposes, funding commercial activities and clinical trails, and more, including potentially for acquisitions. Avanir is focused on treating central nervous system disorders.